Yüklüyor......
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
Hodgkins’ lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphom...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Libertas Academica
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3256979/ https://ncbi.nlm.nih.gov/pubmed/22253553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6637 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|